Orbis Medicines Names Veteran R&D Leader Mikael Dolsten Board Chair
Orbis Medicines, a leader in oral macrocycle drug discovery, today announces the appointment of Mikael Dolsten, M.D., Ph.D., former Chief Scientific Officer, President, Pfizer Research & Development, as Chairperson of the Board of Directors.
Orbis Medicines Raises EUR 90 Million Series A Funding Round to Develop Pipeline of Oral Macrocycles
Orbis Medicines, a leader in oral macrocycle drug discovery, today announces the close of a EUR 90 million Series A funding round, bringing the total amount raised by the company to EUR 116 million.
Orbis Medicines to Expand With New R&D Site in Copenhagen
Orbis Medicines, a leader in oral macrocycle drug discovery, today announced a significant expansion of its operations and capabilities by establishing itself at Symbion’s new biotech hub in Fuglebakken, Copenhagen.
Orbis Medicines and Vivtex Form Research & Exclusive Licensing Collaboration to Support Orbis Development of Next-Generation Orally Dosable ‘nCycles’
Orbis Medicines, a leader in oral macrocycle drug discovery, today announced a research collaboration and option to an exclusive license with Vivtex, a biotech company aiming to transform the development of oral biologic therapies for major diseases.
Orbis Medicines Launches with €26 Million Seed Financing to Transform Macrocycle Drug Development through Next-Generation Orally Dosable ‘nCycles’
Orbis Medicines, a leader in oral macrocycle drug discovery, today announces its launch with a €26 million financing led by global life sciences investor Novo Holdings and European life sciences venture firm Forbion.